NAD agrees with most Prehistin supplement claims
This article was originally published in The Tan Sheet
Executive Summary
Cobalis Corp. supports most print advertising claims that its Prehistin dietary supplement works by raising serum B12 levels and lowering serum levels of immunoglobulin E, which plays a role in allergy response, according to a recent National Advertising Division review. Supported claims included the product is an "all-natural formula," it is "free of side effects" and "has been shown to effectively regulate IgE levels in individuals while significantly increasing serum vitamin B12 levels." However, the watchdog group recommended the Irvine, Calif.-based advertiser discontinue the claim that the product works for "weeks after you stop taking it" and that it is "allergist recommended." The company agreed to comply with NAD's recommendations
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.